Restarting Adderall 30 mg ER After 3–4 Weeks Off
Resume Adderall 30 mg ER at the same dose without titration. A 3–4 week interruption does not require dose reduction or re-titration because tolerance to therapeutic effects does not develop with appropriate stimulant use, and the patient's previously established optimal dose remains valid 1.
Rationale for Same-Dose Resumption
Tolerance to ADHD symptom control does not occur with stimulants. The American Academy of Child and Adolescent Psychiatry states explicitly that there is little evidence of tolerance development to the therapeutic effects of stimulants on ADHD symptoms, and patients most often continue to respond to the same dose even over prolonged treatment periods 1.
Physical dependence and withdrawal are distinct from therapeutic tolerance. While abrupt discontinuation can produce dysphoric mood, fatigue, vivid dreams, insomnia or hypersomnia, increased appetite, and psychomotor changes, these withdrawal phenomena resolve within days and do not alter the therapeutic dose requirement 2.
The FDA-approved dosing for Adderall in adults ranges from 10–50 mg daily, with 30 mg well within the therapeutic window. Maximum doses can reach 40 mg in children and up to 0.9 mg/kg (approximately 65 mg) in adults when lower doses are insufficient 2, 1.
Systematic titration protocols demonstrate that 70–80% of patients achieve optimal response when properly dosed, independent of body weight. The previously established 30 mg dose represents the patient's individualized therapeutic target 1, 3.
Safety Monitoring at Restart
Measure blood pressure and pulse before restarting and at the first follow-up visit. Stimulants typically raise systolic/diastolic pressure by 3–5 mm Hg and heart rate by 5–10 beats/min 1.
Assess for any new cardiovascular symptoms, uncontrolled hypertension, or symptomatic cardiovascular disease that would contraindicate resumption. These are absolute contraindications to stimulant therapy 1, 2.
Screen for any interval development of substance use, active psychosis, or mania, which would require alternative management. Active psychotic disorder or mania are contraindications to stimulant use 1.
Monitor common adverse effects including appetite suppression, insomnia, headache, and weight changes at the first follow-up. These occur in >10% of patients but are typically manageable 1, 4.
Clinical Pearls
Do not assume a "washout period" necessitates starting at a lower dose. The 3–4 week gap does not reset the patient's therapeutic dose requirement, and under-dosing will result in inadequate symptom control 1, 3.
Stimulant effects manifest within hours to days, allowing rapid assessment of efficacy. The patient should experience symptom improvement within the first week of resumption 1, 5.
If the patient reports that 30 mg was previously suboptimal, this is an opportunity to optimize dosing upward by 5–10 mg weekly until symptoms are controlled or dose-limiting adverse effects appear. Maximum adult doses reach 40–50 mg daily in most cases 1, 2.
Avoid the common community practice error of using lower doses than those employed in clinical trials. Studies demonstrate that community treatment programs using lower doses and less frequent monitoring produce inferior outcomes compared with optimal, closely monitored medication management 3.
When to Consider Dose Adjustment
If the patient previously experienced inadequate symptom control at 30 mg, increase by 5–10 mg weekly until optimal response is achieved. Systematic titration yields optimal outcomes in approximately 70% of patients 1, 3.
If the patient develops new intolerable adverse effects at 30 mg (e.g., severe insomnia, marked appetite suppression, cardiovascular symptoms), reduce the dose or adjust timing rather than discontinuing therapy. Many adverse effects can be managed by switching to sustained-release formulations or adjusting dosing schedules 1.
If 30 mg was previously the maximum tolerated dose but symptoms were not fully controlled, consider switching to an alternative stimulant class (e.g., methylphenidate) before moving to non-stimulants. Approximately 40% of patients respond to both stimulant classes, while another 40% respond preferentially to only one 1, 5.